Metformin use among obese patients with prediabetes in Qassim, Saudi Arabia: An observational study.
Diabetes mellitus
Metformin
Obesity
Observational study
Prediabetes
Prevalence
Public health
Journal
Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society
ISSN: 1319-0164
Titre abrégé: Saudi Pharm J
Pays: Saudi Arabia
ID NLM: 9705695
Informations de publication
Date de publication:
Sep 2023
Sep 2023
Historique:
received:
11
05
2023
accepted:
24
06
2023
medline:
31
7
2023
pubmed:
31
7
2023
entrez:
31
7
2023
Statut:
ppublish
Résumé
The high prevalence of prediabetes and diabetes mellitus and its secondary complications in Saudi Arabia is a major healthcare concern. Evidence suggests that despite evidence-based efficacy and safety, metformin is underutilized in prediabetic obese patients. Thus, the aim of this study was to investigate the use of metformin in prediabetic obese patients in the Qassim region of Saudi Arabia. Prediabetic patients' electronic health records were accessed and screened from 2017 to 2021. The inclusion criteria were patients with obesity (BMI ≥ 35) diagnosed with prediabetes, and who received metformin. Patients with chronic kidney disease and those using metformin for other diseases were excluded. The first major endpoint of this study was the rate of metformin use among obese, prediabetic individuals. The second major endpoint was the factors associated with metformin prescribing in our cohort. Descriptive statistics were used to report the primary and secondary outcomes. Data are presented as percentages, means, standard deviations (SDs), medians, and interquartile ranges, as appropriate. All analyses were conducted using Stata version 16.1. A total of 304 prediabetic patients were included in this study after screening the records of 1,789 patients. The average age was found to be 40, and the majority were female (72%). The average BMI was found to be 39.4 kg/m According to the study, metformin is not frequently prescribed to prediabetic obese individuals in the Qassim region of Saudi Arabia. This prevention strategy is a missed opportunity in the management of prediabetes in high-risk patients. Future studies are needed to investigate the root causes of the underuse of metformin and potential interventions to promote evidence-based practice in Saudi Arabia.
Sections du résumé
Background and aims
UNASSIGNED
The high prevalence of prediabetes and diabetes mellitus and its secondary complications in Saudi Arabia is a major healthcare concern. Evidence suggests that despite evidence-based efficacy and safety, metformin is underutilized in prediabetic obese patients. Thus, the aim of this study was to investigate the use of metformin in prediabetic obese patients in the Qassim region of Saudi Arabia.
Methods
UNASSIGNED
Prediabetic patients' electronic health records were accessed and screened from 2017 to 2021. The inclusion criteria were patients with obesity (BMI ≥ 35) diagnosed with prediabetes, and who received metformin. Patients with chronic kidney disease and those using metformin for other diseases were excluded. The first major endpoint of this study was the rate of metformin use among obese, prediabetic individuals. The second major endpoint was the factors associated with metformin prescribing in our cohort. Descriptive statistics were used to report the primary and secondary outcomes. Data are presented as percentages, means, standard deviations (SDs), medians, and interquartile ranges, as appropriate. All analyses were conducted using Stata version 16.1.
Results
UNASSIGNED
A total of 304 prediabetic patients were included in this study after screening the records of 1,789 patients. The average age was found to be 40, and the majority were female (72%). The average BMI was found to be 39.4 kg/m
Conclusion
UNASSIGNED
According to the study, metformin is not frequently prescribed to prediabetic obese individuals in the Qassim region of Saudi Arabia. This prevention strategy is a missed opportunity in the management of prediabetes in high-risk patients. Future studies are needed to investigate the root causes of the underuse of metformin and potential interventions to promote evidence-based practice in Saudi Arabia.
Identifiants
pubmed: 37520674
doi: 10.1016/j.jsps.2023.06.027
pii: S1319-0164(23)00189-5
pmc: PMC10382924
doi:
Types de publication
Journal Article
Langues
eng
Pagination
101694Informations de copyright
© 2023 The Author(s).
Déclaration de conflit d'intérêts
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Références
Healthcare (Basel). 2021 Mar 11;9(3):
pubmed: 33799725
J Pharm Policy Pract. 2020 Sep 14;13:59
pubmed: 32944258
Front Public Health. 2022 Sep 08;10:989072
pubmed: 36159298
PLoS One. 2014 Feb 21;9(2):e88956
pubmed: 24586457
World J Diabetes. 2015 Mar 15;6(2):296-303
pubmed: 25789110
Postgrad Med J. 2006 Apr;82(966):280-4
pubmed: 16597817
Cureus. 2020 Sep 3;12(9):e10227
pubmed: 33042670
Diab Vasc Dis Res. 2019 May;16(3):227-235
pubmed: 30599757
Curr Diabetes Rev. 2016;12(4):359-368
pubmed: 26206092
PLoS One. 2016 Apr 01;11(4):e0152559
pubmed: 27035920
Diabetes Res Clin Pract. 2014 Aug;105(2):141-50
pubmed: 24798950
PLoS One. 2014 Sep 03;9(9):e106935
pubmed: 25184511
Diabetes Care. 2012 Apr;35(4):731-7
pubmed: 22442396
Can Fam Physician. 2009 Apr;55(4):363-9
pubmed: 19366942
Ann Intern Med. 2015 Apr 21;162(8):542-8
pubmed: 25894024
J Am Board Fam Med. 2022 Jul-Aug;35(4):821-826
pubmed: 35896449
J Med Life. 2021 May-Jun;14(3):347-354
pubmed: 34377200
N Engl J Med. 2002 Feb 7;346(6):393-403
pubmed: 11832527
Diabetes Care. 2020 Sep;43(9):1988-1990
pubmed: 32964858
Diabetes Care. 2010 Jan;33(1):49-54
pubmed: 19808929
J Public Health Res. 2021 Feb 22;10(1):2032
pubmed: 33681088
J Family Med Prim Care. 2021 Jan;10(1):143-148
pubmed: 34017717
JAMA. 2019 Oct 1;322(13):1312-1313
pubmed: 31573632
Drugs. 2015 Jul;75(10):1071-94
pubmed: 26059289